eye - International Biopharmaceutical Industry

news

ProQR to lay off 30% of staff following eye drug setback

Dive Brief: ProQR Therapeutics is overhauling its research, cutting staff and trying to find a new way forward for its lead drug after a surprising study failure i...

14 April 2022 news Drug | eye

Continue Reading →

news

Regeneron, in search of an eye gene therapy, turns to a young biotech

Dive Brief: Through a deal announced Wednesday, a German-based biotechnology company has agreed to help Regeneron develop a gene therapy for an inherited retinal d...

11 April 2022 news biotechnology | eye

Continue Reading →

news

A biotech wins the first FDA drug approval in a rare type of eye cancer

Dive Brief: The Food and Drug Administration on Tuesday granted approval to the first drug for a rare cancer of the eye that has spread elsewhere or grown too larg...

27 January 2022 news Biotech | cancer

Continue Reading →

news

Novartis ups investment in gene therapy for the eye with $800M buyout

Novartis' offer comes three months after Gyroscope presented at a medical meeting early data from 13 patients who had been dosed with the gene therapy, called GT005, ...

7 January 2022 news buyout | eye

Continue Reading →

news

Allergan’s eye drug stacks up against Lucentis, but wider market still iffy

Allergan on Thursday touted data from two late-stage trials that showed a drug it in-licensed from a Swiss biotech proved non-inferior to Lucentis in the treatment...

20 July 2018 news Allergan | Drug

Continue Reading →

Current Edition

ProQR to lay off 30% of staff following eye drug setback

Regeneron, in search of an eye gene therapy, turns to a young biotech

A biotech wins the first FDA drug approval in a rare type of eye cancer

Novartis ups investment in gene therapy for the eye with $800M buyout

Allergan’s eye drug stacks up against Lucentis, but wider market still iffy

International Biopharmaceutical Industry